Males exposed to COVID-19 in utero may be at elevated risk of neurodevelopmental disorders medrxivpreprint MassGeneralNews COVID19 SARSCoV2 Neurodevelopment NeurodevelopmentalDisorders
By Pooja Toshniwal PahariaNov 22 2022Reviewed by Aimee Molineux In a recent study posted to the medRxiv* preprint server, researchers investigated the impact of the severe acute respiratory syndrome of coronavirus 2 exposure in utero on the neurodevelopment of children.
The study cohort comprised 18,323 infants delivered between March 1, 2018, and May 31, 2021, at one of the eight Eastern Massachusetts hospitals, including six community-based hospitals, two centers for tertiary care, and their affiliated outpatient connections.
The newborns were linked to their mothers based on the medical record numbers, the sex of the newborns, and the time and date of birth. The mothers’ medical records were characterized based on ICD-10 codes, medications, problem lists, and laboratory-based studies conducted between the dates of the most recent menstruation and discharge for delivery admission.
Three SARS-CoV-2-unexposed children and no SARS-CoV-2-exposed children died before the follow-up period. Males born to PCR-confirmed SARS-CoV-2-positive mothers showed a greater likelihood of being diagnosed with neurodevelopmental diseases in the initial year of life, even after the preterm delivery status was considered. SARS-CoV-2-positive maternal status was associated with a significantly greater neurodevelopmental disease risk among male infants .
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis - BMC MedicineBackground There is growing evidence that patients recovering after a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may have a variety of acute sequelae including newly diagnosed diabetes. However, the risk of diabetes in the post-acute phase is unclear. To solve this question, we aimed to determine if there was any association between status post-coronavirus disease (COVID-19) infection and a new diagnosis of diabetes. Methods We performed a systematic review and meta-analysis of cohort studies assessing new-onset diabetes after COVID-19. PubMed, Embase, Web of Science, and Cochrane databases were all searched from inception to June 10, 2022. Three evaluators independently extracted individual study data and assessed the risk of bias. Random-effects models estimated the pooled incidence and relative risk (RR) of diabetes compared to non-COVID-19 after COVID-19. Results Nine studies with nearly 40 million participants were included. Overall, the incidence of diabetes after COVID-19 was 15.53 (7.91–25.64) per 1000 person-years, and the relative risk of diabetes after COVID-19 infection was elevated (RR 1.62 [1.45–1.80]). The relative risk of type 1 diabetes was RR=1.48 (1.26–1.75) and type 2 diabetes was RR=1.70 (1.32–2.19), compared to non-COVID-19 patients. At all ages, there was a statistically significant positive association between infection with COVID-19 and the risk of diabetes: 65 years: RR=1.68 (1.22–2.30). The relative risk of diabetes in different gender groups was about 2 (males: RR=2.08 [1.27–3.40]; females: RR=1.99 [1.47–2.80]). The risk of diabetes increased 1.17-fold (1.02–1.34) after COVID-19 infection compared to patients with general upper respiratory tract infections. Patients with severe COVID-19 were at higher risk (RR=1.67 [1.25–2.23]) of diabetes after COVID-19. The risk (RR=1.95 [1.85–2.06]) of diabetes was highest in the first 3 months after COVID-19. These results remained after taking confounding factors into acco
Consulte Mais informação »
The negative impact of COVID-19 on working memory revealed using a rapid online quizAlthough coronavirus disease 2019 (COVID-19) affects the respiratory system, it can also have neurological consequences leading to cognitive deficits such as memory problems. The aim of our study was to assess the impact of COVID-19 on working memory function. We developed and implemented an online anonymous survey with a working memory quiz incorporating aspects of gamification to engage participants. 5428 participants successfully completed the survey and memory quiz between 8th December 2020 and 5th July 2021 (68.6% non-COVID-19 and 31.4% COVID-19). Most participants (93.3%) completed the survey and memory quiz relatively rapidly (mean time of 8.84 minutes). Categorical regression was used to assess the contribution of COVID status, age, time post-COVID (number of months elapsed since having had COVID), symptoms, ongoing symptoms and gender, followed by non-parametric statistics. A principal component analysis explored the relationship between subjective ratings and objective memory scores. The objective memory scores were significantly correlated with participants’ own assessment of their cognitive function. The factors significantly affecting memory scores were COVID status, age, time post-COVID and ongoing symptoms. Our main finding was a significant reduction in memory scores in all COVID groups (self-reported, positive-tested and hospitalized) compared to the non-COVID group. Memory scores for all COVID groups combined were significantly reduced compared to the non-COVID group in every age category 25 years and over, but not for the youngest age category (18–24 years old). We found that memory scores gradually increased over a period of 17 months post-COVID-19. However, those with ongoing COVID-19 symptoms continued to show a reduction in memory scores. Our findings demonstrate that COVID-19 negatively impacts working memory function, but only in adults aged 25 years and over. Moreover, our results suggest that working memory deficits with COVID-19 can recov
Consulte Mais informação »
The biological properties of the SARS-CoV-2 E protein in the context of HIV-1The biological properties of the SARS-CoV-2 E protein in the context of HIV-1 UnivOfKansas KUMedCenter SARSCoV2 COVID19 coronavirus covid HIV
Consulte Mais informação »
Chitin-immobilized nanobodies for SARS-CoV-2 detectionChitin-immobilized nanobodies for SARS-CoV-2 detection medrxivpreprint HHU_de SARSCoV2 covid coronavirus COVID19 nanobodies
Consulte Mais informação »
CoviRx: A User-Friendly Interface for Systematic Down-Selection of Repurposed Drug Candidates for COVID-19Although various vaccines are now commercially available, they have not been able to stop the spread of COVID-19 infection completely. An excellent strategy to get safe, effective, and affordable COVID-19 treatments quickly is to repurpose drugs that are already approved for other diseases. The process of developing an accurate and standardized drug repurposing dataset requires considerable resources and expertise due to numerous commercially available drugs that could be potentially used to address the SARS-CoV-2 infection. To address this bottleneck, we created the CoviRx.org platform. CoviRx is a user-friendly interface that allows analysis and filtering of large quantities of data, which is onerous to curate manually for COVID-19 drug repurposing. Through CoviRx, the curated data have been made open source to help combat the ongoing pandemic and encourage users to submit their findings on the drugs they have evaluated, in a uniform format that can be validated and checked for integrity by authenticated volunteers. This article discusses the various features of CoviRx, its design principles, and how its functionality is independent of the data it displays. Thus, in the future, this platform can be extended to include any other disease beyond COVID-19.
Consulte Mais informação »